STAT - Reporting from the frontiers of health and medicine

Health

Biotech

First Opinion

By Adam C. Urato

Health More trial results are being posted to public database, but data quality is lacking, report finds
First Opinion Working with ICER, or around it, on cost-effectiveness estimates
Health Tech Valued for their tech, Silicon Valley digital health companies rely heavily on armies of faraway coaches
Opinions Plus Microbiome drug development: a rapidly evolving field
First Opinion My daughter is gone but her legacy lives on through her writing and phage therapy

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

After backlash, Teva will resume supplies of a critical children’s cancer medicine
Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care
More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help

Don't Miss

By STAT

Special Report

Special Report

Heavyweights

Health

Health

Biotech An FDA advisory panel is reviewing Amarin’s fish oil drug. Follow along for frequent updates
First Opinion The FDA must pull Makena off the market
Health CDC report: 35,000 Americans die of antibiotic-resistant infections each year
Health More trial results are being posted to public database, but data quality is lacking, report finds
First Opinion Working with ICER, or around it, on cost-effectiveness estimates